April Journal-2009.p65 - Association of Biotechnology and Pharmacy

More documents

Recommendations

Info

Current Trends in Biotechnology and Pharmacy Vol. 3 (2) 128-137, April 2009. ISSN 0973-8916 10. Guan, K.L., Jenkins, C.W., Li, Y., Nichols, M.A., Wu, X., O’Keefe, C.L., Matera, A.G. and Xiong, Y. (1994). Growth suppression by p18, a p16INK4/MTSer1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev., 8: 2939–2952. 11. James, M.C. and Peters, G. (2000). Alternative product of the p16/CKDN2A locus connects the Rb and p53 tumor suppressors. Prog. Cell Cycle Res., 4: 71–81. 12. Hannon, G.J. and Beach, D. (1994). p15 INK 4B is a potential effector of TGF-betainduced cell cycle arrest. Nature, 371: 257– 261. 13. Latres, E., Malumbres, M., Sotillo, R., Martin, J., Ortega, S., Martin-Caballero, J., Flores, J.M., Cordon-Cardo, C. and Barbacid, M. (2000). Limited overlapping roles of P15 (INK4b) and P18 (INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J., 19: 3496–3506. 14. Franklin, D.S., Godfrey, V.L., Lee, H., Kovalev, G.I., Schoonhoven, R., Chen- Kiang, S., Su, L. and Xiong, Y. (1998). CDK inhibitors p18 (INK4c) and p27 (KIP1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev., 12: 2899–2911. 15. Hirai, H., Roussel, M.F., Kato, J.Y., Ashmun, R.A. and Sherr, C.J. (1995). Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell Biol., 15: 2672– 2681. 16. Tavera-Mendoza, L.E, Wang, T.T., White, J.H. (2006) p19INK4D and cell death. Cell Cycle, 5: 596–598. 17. Yan, Y., Frisen, J., Lee, M.H., Massague, J. and Barbacid, M. (1997). Ablation of the 136 CDK inhibitor p57KIP2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev., 11: 973–983. 18. Heinen, A., Kremer, D., Gottle, P., Kruse, F., Hasse, B., Lehmann, H., Hartung, H.P., and Kury, P. (2008). The cyclin-dependent kinase inhibitor p57kip2 is a negative regulator of Schwann cell differentiation and in vitro myelination. PNAS, 105: 8748–8753. 19. Sherr, C.J. and Roberts, J.M. (1999). CDK inhibitors: Positive and negative regulators of G 1 -phase progression. Genes & Dev., 13: 1501–1512. 20. Murray, A.W. (2004). Recycling the cell cycle: Cyclins revisited. Cell, 116: 221–234. 21. Polyak, K., Kato, J.Y., Solomon, M.J., Sherr, C.J., Massague, J., Roberts, J.M., and Koff, A. (1994). p27KIP1, a cyclin–Cdk inhibitor, links transforming growth factor-â and contact inhibition to cell cycle arrest. Genes & Dev., 8: 9–22. 22. Lee, M.H., Reynisdottir, I., and Massague, J. (1995). Cloning of p57KIP2, a cyclindependent kinase inhibitor with unique domain structure and tissue distribution. Genes & Dev., 9: 639–649. 23. Ishida, N., Kitagawa, M., Hatakeyama, S., and Nakayama, K. (2000). Phosphorylation at serine 10, a major phosphorylation site of p27 (KIP1). increases its protein stability. J. Biol. Chem., 275: 25146–25154. 24. Nakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., and Loh, D.Y. (1996). Mice lacking p27 (KIP1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, 85: 707–720. 25. Toyoshima, H. and Hunter, T. (1994). p27, a novel inhibitor of G 1 cyclin–Cdk protein kinase activity, is related to p21. Cell, 78: 67–74. Regulation of CDK inhibitors
Current Trends in Biotechnology and Pharmacy Vol. 3 (2) 128-137, April 2009. ISSN 0973-8916 26. Kiyokawa, H., Kineman, R.D., Manova- Todorova, K.O., Soares, V.C., Hoffman, E.S., Ono, M., Khanam, D., Hayday, A.C., Frohman, L.A., and Koff, A. (1996). Enhanced growth of mice lacking the cyclindependent kinase inhibitor function of p27 (KIP1). Cell, 85: 721–732. 27. Pagano, M., Tam, S.W., Theodoras, A.M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P.R., Draetta, G.F., and Rolfe, M. (1995). Role of the ubiquitin–proteasome pathway in regulating abundance of the cyclindependent kinase inhibitor p27. Science, 269: 682–685. 28. Alessandrini, A., Chiaur, D.S., and Pagano, M. (1997). Regulation of the cyclindependent kinase inhibitor p27KIP1 by degradation and phosphorylation. Leukemia 11: 342–345. 29. Zhang, Y., Wang, Z. and Magnuson, N.S. (2007). PIM-1 Kinase-Dependent Phosphorylation of p21Cip1/WAF1 Regulates Its Stability and Cellular Localization in H1299 Cells. Mol Cancer Res., 5: 909–922. 30. Lee, S. and Helfman, D.M. (2004). Cytoplasmic p21Cip1 is involved in Rasinduced inhibition of the ROCK/LIMK/ cofilin pathway. J. Biol. Chem., 279: 1885–1891. 31. Hauck, L., Harms, C., Grothe, D., An, J., Gertz, K., Kronenberg, G., Dietz, R., Endres, M. and von Harsdorf, R. (2007). Critical Role for FoxO3a-Dependent Regulation of p21CIP1/WAF1 in Response to Statin Signaling in cardiac myocytes. Circ. Res., 100: 50–60. 32. Viglietto, G., Motti, M.L., Bruni, P., Melillo, R.M., D’Alessio, A., Califano, D., Vinci, F., Chiappetta, G., Tsichlis, P., Bellacosa, A., Fusco, A. and Santoro, M. (2002). Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor 137 p27kip1 by PKB/AKT-mediated phosphorylation in breast cancer. Nat. Med., 8: 1136– 1144. 33. Liang, J., Zubovitz, J., Petrocelli, T., Kotchetkov, R., Connor, M.K., Han, K., Lee, J.H., Ciarallo, S., Catzavelos, C., Beniston, R., Franssen, E. and Slingerland, J.M. (2002). PKB/AKT phosphorylates p27, impairs nuclear import of p27KIP1 and opposes p27-mediated G 1 arrest. Nat. Med., 8: 1153–1160. 34. Carrano, A.C., Eytan, E., Hershko, A., and Pagano, M. (1999). SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol., 1: 193–199. 35. Zhu, H., Nie, L., Maki, C.G.. (2005). Cdk2- dependent Inhibition of p21CIP1stability via a C-terminal cyclin-binding motif. J Biol Chem., 280: 29282–29288. 36. Fukuchi, K., Nakamura, K., Ichimura, S., Tatsumi, K. and Gomi, K. (2003). The association of cyclin A and cyclin kinase inhibitor p21CIP1 in response to gammairradiation requires the CDK2 binding region, but not the Cy motif. Biochim Biophys Acta., 1642: 163-171. 37. Zeng, Y., Hirano, K., Hirano, M., Nishimura, J., and Kanaide, H. (2000). A cyclindependent kinase inhibitor. Minimal requirements for the nuclear localization of p27 (KIP1). Biochem. Biophys. Res. Commun., 274: 37–42. 38. Boehm, M., Yoshimoto, T., Crook, M.F., Nallamshetty, S., True, A., Nabel, G.J. and Nabel, E.G. (2002). A growth factordependent nuclear kinase phosphorylates p27 (KIP1) and regulates cell cycle progression. EMBO J., 21: 3390–3401. 39. Tsvetkov, L.M., Yeh, K.H., Lee, S.J., Sun, H. and Zhang, H. (1999). p27 (KIP1) ubiquitination and degradation is regulated by the SCF (SKP2) complex through phosphorylated Thr187 in p27. Curr. Biol., 9: 661–664. Jinhwa
Page 2 and 3: Current Trends in Biotechnology and
Page 4 and 5: Association of Biotechnology and Ph
Page 50: Current Trends in Biotechnology and
Page 80 and 81:
Current Trends in Biotechnology and
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
show all

April Journal-2009.p65 - Association of Biotechnology and Pharmacy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?